We hypothesize that dual targeting of HIF1α and CD73 will synergistically reduce EAC cell viability and disrupt pro-tumor microenvironmental pathways, offering a novel therapeutic approach for hypoxic, treatment-resistant EAC. Here, HIF1A is linked to neoplasm.